Junko Takeshita1, Kristina Callis Duffin2, Daniel B Shin3, Gerald G Krueger2, Andrew D Robertson4, Andrea B Troxel5, Abby S Van Voorhees6, Joel M Gelfand3. 1. Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address: Junko.Takeshita@uphs.upenn.edu. 2. Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah. 3. Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 4. National Psoriasis Foundation, Portland, Oregon. 5. Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 6. Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: There is little evidence to guide the establishment of treatment goals for moderate to severe psoriasis in the clinical setting. OBJECTIVE: We sought to compare Dermatology Life Quality Index scores and prescription topical medication use between patients with clear versus almost clear skin. METHODS: This was a multicenter cross-sectional study of 97 patients with clear skin and 441 patients with almost clear skin receiving current systemic therapy or phototherapy for a primary indication of plaque psoriasis evaluated at 1 of 10 US outpatient dermatology sites participating in the Dermatology Clinical Effectiveness Research Network. RESULTS: In adjusted analyses, patients with clear versus almost clear skin were more likely to report no impact of psoriasis on quality of life (relative risk 1.60; 95% confidence interval 1.37-1.86). Patients with clear versus almost clear skin were also more likely to report no prescription topical medication use in the preceding week (relative risk 2.08; 95% confidence interval 1.73-2.49). LIMITATIONS: Cross-sectional design prohibits longitudinal assessment of outcomes. CONCLUSIONS: Clinically important differences in quality of life and prescription topical medication use exist between patients with clear versus almost clear skin. Collectively, our results indicate that achievement of clear skin may be an important clinical distinction among patients with moderate to severe psoriasis.
BACKGROUND: There is little evidence to guide the establishment of treatment goals for moderate to severe psoriasis in the clinical setting. OBJECTIVE: We sought to compare Dermatology Life Quality Index scores and prescription topical medication use between patients with clear versus almost clear skin. METHODS: This was a multicenter cross-sectional study of 97 patients with clear skin and 441 patients with almost clear skin receiving current systemic therapy or phototherapy for a primary indication of plaque psoriasis evaluated at 1 of 10 US outpatient dermatology sites participating in the Dermatology Clinical Effectiveness Research Network. RESULTS: In adjusted analyses, patients with clear versus almost clear skin were more likely to report no impact of psoriasis on quality of life (relative risk 1.60; 95% confidence interval 1.37-1.86). Patients with clear versus almost clear skin were also more likely to report no prescription topical medication use in the preceding week (relative risk 2.08; 95% confidence interval 1.73-2.49). LIMITATIONS: Cross-sectional design prohibits longitudinal assessment of outcomes. CONCLUSIONS: Clinically important differences in quality of life and prescription topical medication use exist between patients with clear versus almost clear skin. Collectively, our results indicate that achievement of clear skin may be an important clinical distinction among patients with moderate to severe psoriasis.
Keywords:
Dermatology Life Quality Index; Physician Global Assessment; Psoriasis Area and Severity Index; patient-reported outcome; psoriasis; quality of life
Authors: M-L Schaarschmidt; N Umar; A Schmieder; D D Terris; M Goebeler; S Goerdt; W K Peitsch Journal: J Eur Acad Dermatol Venereol Date: 2012-01-06 Impact factor: 6.166
Authors: S Devaux; A Castela; E Archier; A Gallini; P Joly; L Misery; S Aractingi; F Aubin; H Bachelez; B Cribier; D Jullien; M Le Maître; M-A Richard; J-P Ortonne; C Paul Journal: J Eur Acad Dermatol Venereol Date: 2012-05 Impact factor: 6.166
Authors: Howa Yeung; Junko Takeshita; Nehal N Mehta; Stephen E Kimmel; Alexis Ogdie; David J Margolis; Daniel B Shin; Rosemary Attor; Andrea B Troxel; Joel M Gelfand Journal: JAMA Dermatol Date: 2013-10 Impact factor: 10.282
Authors: K Callis Duffin; H Yeung; J Takeshita; G G Krueger; A D Robertson; A B Troxel; D B Shin; A S Van Voorhees; J M Gelfand Journal: Br J Dermatol Date: 2014-03 Impact factor: 9.302
Authors: U Mrowietz; K Kragballe; K Reich; P Spuls; C E M Griffiths; A Nast; J Franke; C Antoniou; P Arenberger; F Balieva; M Bylaite; O Correia; E Daudén; P Gisondi; L Iversen; L Kemény; M Lahfa; T Nijsten; T Rantanen; A Reich; T Rosenbach; S Segaert; C Smith; T Talme; B Volc-Platzer; N Yawalkar Journal: Arch Dermatol Res Date: 2010-09-21 Impact factor: 3.017
Authors: Ladan Afifi; Lindsey Shankle; April W Armstrong; Marc Boas; Alisha Bridges; Vivian Chiguil; Frank Doris; Kristina Callis Duffin; Eric Fielding; Roy Fleischmann; Joel M Gelfand; Matthew Kiselica; Catherine Kiselica; Brian LaFoy; John J Latella; Junko Takeshita; Sarah Truman; Marilyn T Wan; Vickie Wilkerson; Jashin J Wu; Michael P Siegel; Wilson Liao Journal: J Psoriasis Psoriatic Arthritis Date: 2017
Authors: Vanina L Taliercio; Ashley M Snyder; Lisa B Webber; Adelheid U Langner; Bianca E Rich; Abram P Beshay; Dominik Ose; Joshua E Biber; Rachel Hess; Jamie L W Rhoads; Aaron M Secrest Journal: J Clin Aesthet Dermatol Date: 2021-06-01
Authors: David Pariser; Ellen Frankel; Joel Schlessinger; Yves Poulin; Ronald Vender; Richard G Langley; Xiangyi Meng; Adriana Guana; Judit Nyirady Journal: Dermatol Ther (Heidelb) Date: 2017-12-07